Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProAgio in CRC
NCT06867822Phase 1Suspended
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes, PEGylated Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of proagio in colorectal cancer (CRC) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Adverse Events up to 18 months. Started Jul 2025; status: suspended.
02
Drugs
proagio
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06867822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06867822.